MediGene AG

euro adhoc: MediGene AG
MediGene Receives Approval for the Three-Months Sustained Release Product Eligard® (previously known as Leuprogel®) (E)

--------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. --------------------------------------------------------------------- Martinsried - San Diego, January 26, 2004: The German-American biotechnology company MediGene AG (Frankfurt, Prime Standard: MDG) has received marketing authorization for Germany from the Bundesinstitut für Arzneimittel und Medizinprodukte (= Federal Institute for pharmaceuticals and medical devices), BfArM, for the three-months sustained release product of the anti-cancer drug Eligard® (previously known as Leuprogel®) for the treatment of advanced prostate cancer. The corresponding one-month sustained release product of this drug had received marketing authorization at the beginning of December 2003. The three-months sustained release product offers additional applications of Eligard®, thus enhancing its competitiveness. As announced on January 14, MediGene's partner Yamanouchi will take on market launch and sale of Eligard®. As part of the agreement with Yamanouchi, MediGene will receive a milestone payment for this approval of the three-months sustained release product. MediGene and Yamanouchi are planning to submit marketing authorization applications in other European countries as well. Within the framework of the so-called "Mutual Recognition Procedure", the German approval will serve as a reference there. MediGene had acquired the license for commercialization of Eligard® in Europe from the US company Atrix Laboratories, Inc. in April 2001. Contact: MediGene AG, Email: investor@medigene.com, Fax: ++49-89-8565-2920 Julia Hofmann, Public Relations, ph.: ++49-89-8565-3324 Dr. Michael Nettersheim, Investor Relations, ph.:++49-89-8565-2946 end of announcement euro adhoc 26.01.2004 --------------------------------------------------------------------- Further inquiry note: Jessica Kern Tel.: +49 (0)89 8565 2986 E-mail: j.kern@medigene.com Branche: Biotechnology ISIN: DE0005020903 WKN: 502090 Index: CDAX, Prime All Share, Prime Standard, Technologie All Share Börsen: Frankfurter Wertpapierbörse / regulated dealing Niedersächsische Börse zu Hannover / free trade Berliner Wertpapierbörse / free trade Bayerische Börse / free trade Hamburger Wertpapierbörse / free trade Bremer Wertpapierbörse (BWB) / free trade Börse Düsseldorf / free trade Baden-Württembergische Wertpapierbörse / free trade

Das könnte Sie auch interessieren: